New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For DELL;ADNC;MRK;TSN;CTRP;GDOT;VVUS;NFLX;MCK;MAT;LTM;ALKS;ELN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>
December 12, 2014
16:33 EDTMRKStocks finish week lower amid steep decline in oil prices
Subscribe for More Information
15:19 EDTGDOTGreen Dot files to sell 6.13M shares of Class A common stock for holders
Subscribe for More Information
14:56 EDTGDOTGreen Dot requests withdrawal of registration statement
The company requests withdrawal of the Registration Statement, File No. 333-200873, because it was inadvertently filed as form type “S-3” instead of form type “S-3ASR.” The company intends to file a new automatic shelf registration statement with the proper EDGAR codes to identify it as a filing on form type “S-3ASR” shortly after submitting this request.
12:22 EDTNFLXNetflix introduces Atlas telemetry platform
Subscribe for More Information
06:33 EDTNFLXNetflix responds to FCC Commissioner's fast lanes allegations, TechCrunch says
Subscribe for More Information
06:14 EDTGDOTGreen Dot files to sell 6.13M shares for holders
December 11, 2014
16:01 EDTNFLXOptions Update; December 11, 2014
Subscribe for More Information
09:37 EDTNFLXActive equity options trading
Subscribe for More Information
08:27 EDTMRKNewLink Genetics falls after Ebola vaccine trial suspended
Shares of NewLink Genetics (NLNK) are falling in pre-market trading after a clinical trial of the Ebola vaccine being developed by the company and partner Merck (MRK) was temporarily suspended as a precautionary measure after four patients complained of joint pains in their hands and feet, the University of Geneva Hospital said. The trials are scheduled to resume next month in up to 15 volunteers after checks to make sure that the joint pain symptoms were benign and temporary, the hospital added. Shares of NewLink are down 6.5% to $34.50 in early morning trading following the news, while Merck shares are indicated to open fractionally higher.
07:46 EDTMATBenchmark to hold a conference
Micro Cap Discovery Conference is being held in Chicago on December 11.
December 10, 2014
16:00 EDTMRKOptions Update; December 10, 2014
Subscribe for More Information
13:45 EDTMRKMerck's Gardasil 9 approved by FDA
Subscribe for More Information
12:06 EDTTSNUSDA lowers 2014 meat production forecast
Subscribe for More Information
09:53 EDTTSNTyson sees capturing over $500M in Hillshire synergies by end year three
Subscribe for More Information
09:49 EDTTSNTyson Foods reiterates temporary halt on China expansion plans
09:44 EDTTSNTyson Foods targeting consistent growth, less volatile earnings
Subscribe for More Information
09:25 EDTTSNTyson Foods lists 'rapid de-leveraging,' acquisitions among cash priorities
Tyson Foods said its priorities for cash include rapid de-leveraging from $1B+ cash flows and $500M+ from sale of Latin American operations; acquisitions to fulfill its growth strategy; and returning cash to shareholders through share repurchases and dividends.
09:19 EDTTSNTyson Foods repeats FY15 adjusted EPS view $3.30-$3.40, consensus $3.41
Subscribe for More Information
08:47 EDTMRKMerck, IBCSG, BIG announce opening of PANACEA study
The International Breast Cancer Study Group, Breast International Group, and Merck announced the opening of the PANACEA study, a global collaborative study exploring a new way to treat HER2+ breast cancer that has become resistant to the current standard of care. The PANACEA study will investigate the use of pembrolizumab in combination with trastuzumab to evaluate whether the addition of an anti-PD-1 therapy can reverse trastuzumab resistance in patients with HER2+ breast cancer whose cancer has spread while on trastuzumab therapy. The trial, “Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2+ Breast Cancer,” is a Phase 1b/2 study in patients with HER2+ breast cancer whose cancer has spread while on treatment with trastuzumab. Primary outcome measures of the study are recommended dose and efficacy and safety profile of pembrolizumab in combination with trastuzumab. Response will be assessed by RECIST 1.1 criteria. Secondary outcome measures include safety and tolerability, disease control, duration of response, time to progression, progression-free survival and overall survival. The study is enrolling adult females with unresectable or metastatic breast adenocarcinoma with confirmed HER2-positivity. There are 10 sites participating in the study across Europe and Australia: Peter MacCallum Cancer Centre and Westmead Hospital in Australia; Medical University of Vienna in Austria; Jules Bordet Institute and CHU Sart Tilman in Belgium; Institut de Cancérologie de l’OUEST, Centre Léon Bérard and Institut Gustave Roussy in France; and Istituto Europeo di Oncologia Milano and Azienda USL4 Prato in Italy.
08:32 EDTMRKMerck announces early findings showing 18.5% overall response rate with Keytruda
Merck announced early study findings demonstrating an overall response rate of 18.5% with KEYTRUDA, the company’s anti-PD-1 therapy, as assessed by RECIST v1.1, central review in PD-L1 positive, advanced triple-negative breast cancer – one of the most aggressive forms of breast cancer. At the time of analysis, the median duration of response had not been reached with three of five responders on therapy for 11 months or more. These early findings, from the ongoing Phase 1b KEYNOTE-012 study, were shared today for the first time as part of the official press program at the 2014 San Antonio Breast Cancer Symposium and will be presented in an oral session at 10:45 a.m. CST by Dr. Rita Nanda, the University of Chicago. Data presented were from a cohort of the ongoing Phase 1b KEYNOTE-012 study which evaluated KEYTRUDA monotherapy at 10 mg/kg every two weeks in patients with advanced TNBC whose tumors were determined to be positive for PD-L1 expression. As measured by Merck’s proprietary PD-L1 immunohistochemistry clinical trial assay, tumors were considered to be PD-L1 positive if staining was present in the stroma or in greater than or equal to one percent of tumor cells. In the study, 58 percent of patients screened had tumors determined to be positive for PD-L1 expression. Most patients enrolled in this study had received two or more prior chemotherapies for metastatic disease and 87.5 percent had received prior neo-adjuvant or adjuvant therapy.
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use